Unity Biotechnology falls as eye disease treatment fails in mid-stage trial

Shares of Unity Biotechnology UBX.O fall 35.3% to $1.18

Drug developer says its treatment for a type of eye disease failed to meet the main goal of a mid-stage trial

Co was testing the treatment in patients with diabetic macular edema (DME), an eye condition that causes swelling in the retina in those who have poor vision despite prior treatment

Co says the treatment, UBX1325, did not meet the main goal of statistical non-inferiority to Regeneron's REGN.O Eylea, the standard of care treatment for patients with DME

Co, however, says UBX1325 showed improvements in clarity of vision of over 5 letters at weeks 24 and 36

Co anticipates the complete results from the remaining patients in Q2 of 2025

Stock had fallen 49.4% in 2024